Impact of Electronic Cigarette Vaping on Cerebral Ischemia: What We Know So Far

被引:4
作者
Siegel, Jonathan [1 ]
Patel, Shahil H. [1 ]
Mankaliye, Berk [1 ]
Raval, Ami P. [1 ,2 ]
机构
[1] Univ Miami, Peritz Scheinberg Cerebral Vasc Dis Res Lab, Leonard M Miller Sch Med, Dept Neurol, Neurol Res Bldg,1420 NW 9th Ave Room 203H, Miami, FL 33136 USA
[2] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL 33136 USA
关键词
Nicotine; Metabolism; Blood-brain barrier; Cerebral blood flow; Endothelial cells; Sex difference; NICOTINIC ACETYLCHOLINE-RECEPTORS; TOBACCO PRODUCT USE; UNITED-STATES; BLOOD-FLOW; NEURONAL DEATH; BRAIN EDEMA; LIQUID-CHROMATOGRAPHY; SIGNALING PATHWAYS; SALIVARY COTININE; OXIDATIVE STRESS;
D O I
10.1007/s12975-022-01011-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Electronic cigarettes (ECs) are battery-powered nicotine delivery devices that have rapidly gained popularity and attention globally. ECs work by heating a liquid to produce an aerosol that usually contains nicotine, flavoring compounds, and other chemicals, which are inhaled during vaping. EC aerosols are depicted to contain a lower number and overall quantity of harmful toxicants than conventional cigarettes (CCs). However, emerging research indicates that EC aerosols contain harmful ingredients including ultrafine particles, volatile organic compounds, and heavy metals. One common ingredient found in both CCs and ECs is nicotine, which has been shown to be both highly addictive and toxic. Particularly relevant to our current review, there is an enormous amount of literature that shows that smoking-derived nicotine exacerbates ischemic brain damage. Therefore, the question arises: will EC use impact the outcome of stroke? ECs are highly popular and relatively new in the market; thus, our understanding about the long-term effects of EC use on brain are lacking. The current review strives to extrapolate the existing understanding of the nicotine-induced effects of conventional smoking on the brain to the possible effects that ECs may have on the brain, which may ultimately have a potential for adverse stroke risk or severity.
引用
收藏
页码:923 / 938
页数:16
相关论文
共 50 条
  • [21] Implications of VIP and PACAP in Parkinson's Disease: What do we Know So Far?
    Oliveira de Souza, Filipe Resende
    Ribeiro, Fabiola Mara
    d'Almeida Lima, Patricia Maria
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (09) : 1703 - 1715
  • [22] Unraveling Cell Death Pathways during Malaria Infection: What Do We Know So Far?
    Sena-dos-Santos, Camille
    Braga-da-Silva, Cintia
    Marques, Diego
    Azevedo dos Santos Pinheiro, Jhully
    Ribeiro-dos-Santos, Andrea
    Cavalcante, Giovanna C.
    CELLS, 2021, 10 (02) : 1 - 29
  • [23] Cellular and Molecular Pathophysiology of Traumatic Brain Injury: What Have We Learned So Far?
    Freire, Marco Aurelio M.
    Rocha, Gabriel Sousa
    Bittencourt, Leonardo Oliveira
    Falcao, Daniel
    Lima, Rafael Rodrigues
    Cavalcanti, Jose Rodolfo Lopes P.
    BIOLOGY-BASEL, 2023, 12 (08):
  • [24] Mitochondrial Toxicant-Induced Neuronal Apoptosis in Parkinson's Disease: What We Know so Far
    Sivagurunathan, Narmadhaa
    Gnanasekaran, Priyadharshini
    Calivarathan, Latchoumycandane
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2023, 13 : 1 - 13
  • [25] Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies
    Rabaan, Ali A.
    Abas, Abdul Hawil
    Tallei, Trina Ekawati
    Al-Zaher, Mona A.
    Al-Sheef, Noor M.
    Fatimawali
    Al-Nass, Esraa Z.
    Al-Ebrahim, Eba A.
    Effendi, Yunus
    Idroes, Rinaldi
    Alhabib, Mather F.
    Al-Fheid, Hussain A.
    Adam, Ahmad Akroman
    Bin Emran, Talha
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [26] Metal-based nanomaterials in aquatic environments: What do we know so far about their ecotoxicity?
    Ale, Analia
    Andrade, Victoria S.
    Gutierrez, Maria Florencia
    Ayech, Alinne
    Monserrat, Jose M.
    Desimone, Martin F.
    Cazenave, Jimena
    AQUATIC TOXICOLOGY, 2024, 275
  • [27] Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far
    Shalaby, Youssef M.
    Al Aidaros, Anas
    Valappil, Anjana
    Ali, Bassam R.
    Akawi, Nadia
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [28] Polyphenols Targeting NF-0B Pathway in Neurological Disorders: What We Know So Far?
    Al Mamun, Abdullah
    Shao, Chuxiao
    Geng, Peiwu
    Wang, Shuanghua
    Xiao, Jian
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2024, 20 (04): : 1332 - 1355
  • [29] Pediatric Myocarditis: What Have We Learnt So Far?
    Pomiato, Elettra
    Perrone, Marco Alfonso
    Palmieri, Rosalinda
    Gagliardi, Maria Giulia
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (05)
  • [30] Rabies virus in white-nosed coatis (Nasua narica) in Mexico: what do we know so far?
    Puebla-Rodriguez, Paola
    Almazan-Marin, Cenia
    Garces-Ayala, Fabiola
    Rendon-Franco, Emilio
    Chavez-Lopez, Susana
    Gomez-Sierra, Mauricio
    Sandoval-Borja, Albert
    Martinez-Solis, David
    Escamilla-Rios, Beatriz
    Sauri-Gonzalez, Isaias
    Alonzo-Gongora, Adriana
    Lopez-Martinez, Irma
    Arechiga-Ceballos, Nidia
    FRONTIERS IN VETERINARY SCIENCE, 2023, 10